Please login to the form below

Not currently logged in
Email:
Password:

Merrimack Pharma

This page shows the latest Merrimack Pharma news and features for those working in and with pharma, biotech and healthcare.

Ipsen buys cancer business from stripped down Merrimack

Ipsen buys cancer business from stripped down Merrimack

Ipsen buys cancer business from stripped down Merrimack. Deal includes pancreatic cancer therapy Onivyde which it hopes will gain first-line approval. ... French drugmaker Ipsen will pay $575m to buy Merrimack Pharma's oncology business, headed by

Latest news

  • Daiichi pulls study of patritumab in lung cancer Daiichi pulls study of patritumab in lung cancer

    Other companies working on HER3 inhibitors include Merrimack Pharma, whose seribantumab (MM-121) candidate is in phase III, as well as GlaxoSmithKline with GKS2849330 (phase I) and Roche's Genentech unit ... The antibody was developed by Daiichi Sankyo's

  • Baxter and Merrimack file pancreatic cancer drug in EU Baxter and Merrimack file pancreatic cancer drug in EU

    Baxter and Merrimack file pancreatic cancer drug in EU. MM-398 is thought to help direct the active drug into tumours. ... Baxter and Merrimack Pharma have filed for approval of their pancreatic cancer therapy MM-398 in the EU, a few days after the FDA

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics